Actualités

The Danish drugmaker alleges Lilly used outdated trial data to claim Zepbound beats Wegovy on weight loss

Novo Nordisk (NYSE:NVO) has filed a federal lawsuit against Eli Lilly, alleging that its rival’s advertising campaigns for blockbuster GLP-1 obesity and diabetes drugs mislead consumers about the effectiveness of competing treatments. The complaint, filed on July 21, 2026, in the US District...

ENTX stock jumps 35% in a month after the FDA backs a streamlined phase III plan for oral osteoporosis candidate EB613, bringing a key regulatory milestone into focus.

The lawsuit alleges that Eli Lilly misled consumers by using outdated clinical trial data to make its drugs appear more effective than Novo's.

Novo Nordisk alleges Eli Lilly falsely advertised Zepbound and Mounjaro by claiming the drugs outperform Wegovy and Ozempic.

Novo Nordisk (NVO) is suing Eli Lilly (LLY) for misleading advertising. Morning Brief host Julie Hyman discusses the details with Yahoo Finance Breaking Business News Reporter Jake Conley and Payne Capital Management president Ryan Payne.

Drugmakers clash over marketing of blockbuster obesity and diabetes treatmentsNovo Nordisk Inc. (NYSE:NVO) has filed a lawsuit against Eli Lilly and Company (NYSE:LLY) and Lilly USA, LLC, accusing its rival of false advertising and unfair competition in a dispute over marketing claims for their leading GLP-1 medicines.

Danish pharmaceuticals heavyweight Novo Nordisk said Tuesday it is suing its arch US rival, Eli Lilly, over "false and materially misleading" adverts for their competing weight-loss and anti-diabetes treatments. Novo Nordisk has developed a molecule called semaglutide, while Eli Lilly developed rival molecule tirzepatide. 

Novo alleges that Lilly’s Zepbound advertisements compare the drug’s highest approved dose with lower doses of Wegovy.

Investing.com -- The clash between pharma titans Novo Nordisk and Eli Lilly just escalated from the pharmacy counter to the courtroom. Novo Nordisk Inc. filed a lawsuit in the U.S. District Court for the District of New Jersey against Eli Lilly and Company and Lilly USA, LLC, alleging multiple violations of federal and state false advertising and unfair competition laws under the Lanham Act. The lawsuit takes aim at Lilly’s aggressive direct-to-consumer (DTC) advertising campaigns for its blockb

Novo Nordisk claims Eli Lilly aired misleading ads comparing the pharma companies' respective weight-loss drugs, Wegovy and Zepbound.

Ozempic maker Novo Nordisk has filed a lawsuit against Eli Lilly, arguing it uses deceptive advertising to mislead consumers. The complaint accuses Eli Lilly of using outdated studies to promote its branded GLP-1 drugs, Mounjaro and Zepbound, as helping consumers lose significantly more weight on average than Novo Nordisk’s Ozempic and Wegovy.

The maker of Ozempic and Wegovy says its competitor is misleading consumers by citing outdated weight-loss data in advertisements.

The maker of Ozempic and Wegovy says its competitor is misleading consumers by citing outdated weight-loss data in advertisements.

Novo says Lilly's TV and social media campaigns cite outdated trial data to make Zepbound and Mounjaro look more effective than rival injections

By Maggie Fick LONDON, July 21 (Reuters) - Novo Nordisk said on Tuesday it was suing rival Eli Lilly in U.S. federal court, accusing the U.S. drugmaker of false advertising in claiming its weight-loss

(Bloomberg) -- Novo Nordisk A/S is suing Eli Lilly & Co. in US federal court, claiming that Lilly’s advertising for its blockbuster obesity shot Zepbound and diabetes injection Mounjaro is misleading as competition between the two drugmakers escalates.Most Read from BloombergYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshot’s Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memor

Novo Nordisk has accused arch-rival Eli Lilly of peddling false claims about its weight-loss products in advertising campaigns, marking the latest...

Billionaire investors such as Peter Thiel and Christian Angermayer are believers in the benefits of using psychedelics derived from magic mushrooms...

Eli Lilly (NYSE:LLY) has joined the Illumina Billion Cell Atlas as a founding member, forming an alliance focused on mapping human disease biology using large-scale genomic data and AI-driven drug discovery. The collaboration aims to build a detailed reference of cellular and genetic information across diseases, supporting the discovery of new drug targets. Eli Lilly enters this alliance with strong recent stock performance, with the share price at $1,146.9 and the stock up 51.5% over the...

President Donald Trump recently praised Eli Lily at a public event and called it “a great company” and highlighted its planned $3.5 billion investment for a manufacturing plant in Pennsylvania. However, Claude AI begs to differ from Trump. The AI agent recently sold its entire stake in Eli Lilly and Company (NYSE:LLY). Claude AI said […]

In the latest trading session, Eli Lilly (LLY) closed at $1, marking a -2.73% move from the previous day.

Gene-editing biotech targets up to $242.7 million valuation, with initial ASCVD trial data expected in 2027.

Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index shedding 1.1% and t

The healthcare giant's pharma division is booming, but analysts on its latest call wanted to know if that's enough to cover for a sudden slowdown in MedTech.

Investors have flocked to Eli Lilly for exposure to the high-growth weight loss drug market.

Management lifted its profit outlook, and investors have more than quadrupled that bet. The question now is what they're really paying for.

Novo Nordisk wins EU approval for the first GLP-1 obesity tablet, expanding Wegovy's reach, but tougher competition keeps the broader investment outlook in focus.

Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

JNJ raised its 2026 outlook after strong Q2 results, but can new medicines and pipeline strength outweigh patent losses and MedTech challenges?